{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:37:13Z","timestamp":1789000633026,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100000194","name":"Nova Scotia Health Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000194","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","award":["RGPIN 2017-06094"],"award-info":[{"award-number":["RGPIN 2017-06094"]}],"id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"DOI":"10.1186\/s12954-024-01069-9","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T23:43:45Z","timestamp":1723506225000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["An individual-based dynamic model to assess interventions to mitigate opioid overdose risk"],"prefix":"10.1186","volume":"21","author":[{"given":"Kirsten","family":"Gallant","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Lukeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"key":"1069_CR1","unstructured":"United Nations. World Drug Report 2023. [https:\/\/www.unodc.org\/unodc\/en\/data-and-analysis\/world-drug-report-2023.html]"},{"key":"1069_CR2","unstructured":"Government of Canada. Opioid- and Stimulant-related Harms in Canada. 2023."},{"issue":"6","key":"1069_CR3","doi-asserted-by":"publisher","first-page":"224","DOI":"10.24095\/hpcdp.38.6.02","volume":"38","author":"L Belzak","year":"2018","unstructured":"Belzak L, Halverson J. The opioid crisis in Canada: a national perspective. Health Promot Chronic Dis Prev Can. 2018;38(6):224\u201333.","journal-title":"Health Promot Chronic Dis Prev Can"},{"key":"1069_CR4","unstructured":"Strang JS, McDonald R. Preventing opioid overdose deaths with take-home naloxone. Publications Office; 2016."},{"issue":"11","key":"1069_CR5","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1001\/jamaneurol.2018.1693","volume":"75","author":"V Alambyan","year":"2018","unstructured":"Alambyan V, Pace J, Miller B, et al. The emerging role of inhaled heroin in the opioid epidemic: a review. JAMA Neurol. 2018;75(11):1423\u201334. https:\/\/doi.org\/10.1001\/jamaneurol.2018.1693.","journal-title":"JAMA Neurol"},{"key":"1069_CR6","volume-title":"Office of the Chief Coroner for Ontario and Ontario Agency for Health Protection and Promotion (Public Health Ontario). Changing circumstances surrounding opioid-related deaths in Ontario during the COVID-19 pandemic","author":"T Gomes","year":"2021","unstructured":"Gomes T, Murray R, Kolla G, Leece P, Bansal S, Besharah J, Cahill T, Campbell T, Fritz A, Munro C, Toner L, Watford J, on behalf of the Ontario Drug Policy Research Network. Office of the Chief Coroner for Ontario and Ontario Agency for Health Protection and Promotion (Public Health Ontario). Changing circumstances surrounding opioid-related deaths in Ontario during the COVID-19 pandemic. Toronto, ON: Ontario Drug Policy Research Network; 2021."},{"key":"1069_CR7","unstructured":"Drug Enforcement Administration. National Drug Threat Assessment Summary 2013."},{"key":"1069_CR8","unstructured":"National Institute on Drug Abuse. Drug Overdose Death Rates 2023. https:\/\/nida.nih.gov\/research-topics\/trends-statistics\/overdose-death-rates"},{"issue":"7","key":"1069_CR9","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1056\/NEJMp1615145","volume":"376","author":"RG Frank","year":"2017","unstructured":"Frank RG, Pollack HA. Addressing the fentanyl threat to public health. N Engl J Med. 2017;376(7):605\u20137.","journal-title":"N Engl J Med"},{"key":"1069_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12954-019-0336-0","volume":"17","author":"N Maghsoudi","year":"2020","unstructured":"Maghsoudi N, McDonald K, Stefan C, Beriault D, Mason K, Barnaby L, et al. Evaluating networked drug checking services in Toronto, Ontario: study protocol and rationale. Harm Reduct J. 2020;17:1\u201310.","journal-title":"Harm Reduct J"},{"issue":"3","key":"1069_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/10550880802122646","volume":"27","author":"PL Tenore","year":"2008","unstructured":"Tenore PL. Psychotherapeutic benefits of opioid agonist therapy. J Addict Dis. 2008;27(3):49\u201365.","journal-title":"J Addict Dis"},{"key":"1069_CR12","doi-asserted-by":"crossref","unstructured":"Pardo B, Kilmer B, Caulkins JP. Assessing the evidence on supervised drug consumption sites. Volume 5. RAND; 2018 Dec.","DOI":"10.7249\/WR1261"},{"key":"1069_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-021-10497-2","volume":"21","author":"A Moustaqim-Barrette","year":"2021","unstructured":"Moustaqim-Barrette A, Dhillon D, Ng J, Sundvick K, Ali F, Elton-Marshall T, Leece P, Rittenbach K, Ferguson M, Buxton JA. Take-home naloxone programs for suspected opioid overdose in community settings: a scoping umbrella review. BMC Public Health. 2021;21:1\u20136.","journal-title":"BMC Public Health"},{"key":"1069_CR14","doi-asserted-by":"crossref","unstructured":"Wakeman SE. Harm reduction approaches for opioid use disorder. Treat Opioid Addict. 2019:169\u201380.","DOI":"10.1007\/978-3-030-16257-3_8"},{"issue":"4","key":"1069_CR15","doi-asserted-by":"publisher","first-page":"e249","DOI":"10.1016\/S2468-2667(21)00007-4","volume":"6","author":"C Keen","year":"2021","unstructured":"Keen C, Kinner SA, Young JT, Snow K, Zhao B, Gan W, et al. Periods of altered risk for non-fatal drug overdose: a self-controlled case series. Lancet Public Health. 2021;6(4):e249\u201359.","journal-title":"Lancet Public Health"},{"issue":"4","key":"1069_CR16","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/j.1465-3362.2009.00057.x","volume":"28","author":"MA Stoov\u00e9","year":"2009","unstructured":"Stoov\u00e9 MA, Dietze PM, Jolley D. Overdose deaths following previous non-fatal heroin overdose: record linkage of ambulance attendance and death registry data. Drug Alcohol Rev. 2009;28(4):347\u201352.","journal-title":"Drug Alcohol Rev"},{"issue":"9","key":"1069_CR17","doi-asserted-by":"publisher","first-page":"592","DOI":"10.7326\/0003-4819-159-9-201311050-00005","volume":"159","author":"IA Binswanger","year":"2013","unstructured":"Binswanger IA, Blatchford PJ, Mueller SR, Stern MF. Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann Intern Med. 2013;159(9):592\u2013600.","journal-title":"Ann Intern Med"},{"key":"1069_CR18","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.drugpo.2017.05.029","volume":"46","author":"BD Marshall","year":"2017","unstructured":"Marshall BD, Krieger MS, Yedinak JL, Ogera P, Banerjee P, Alexander-Scott NE, et al. Epidemiology of fentanyl-involved drug overdose deaths: a geospatial retrospective study in Rhode Island, USA. Int J Drug Policy. 2017;46:130\u20135.","journal-title":"Int J Drug Policy"},{"key":"1069_CR19","doi-asserted-by":"publisher","unstructured":"Cerd\u00e1 M, Jalali MS, Hamilton AD, DiGennaro C, Hyder A, Santaella-Tenorio J, Kaur N, Wang C, Keyes KM. A systematic review of simulation models to track and address the opioid crisis. Epidemiologic reviews. 2021;43(1):147-65. https:\/\/doi.org\/10.1093\/epirev\/mxab013","DOI":"10.1093\/epirev\/mxab013"},{"key":"1069_CR20","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1007\/s11538-019-00605-0","volume":"81","author":"NA Battista","year":"2019","unstructured":"Battista NA, Pearcy LB, Strickland WC. Modeling the prescription opioid epidemic. Bull Math Biol. 2019;81:2258\u201389.","journal-title":"Bull Math Biol"},{"key":"1069_CR21","doi-asserted-by":"publisher","unstructured":"Brandon DL, Marshall S, Galea. Formalizing the role of Agent-based modeling in causal inference and epidemiology. Am J Epidemiol. 2015;181(2):92\u20139. https:\/\/doi.org\/10.1093\/aje\/kwu274","DOI":"10.1093\/aje\/kwu274"},{"issue":"3","key":"1069_CR22","doi-asserted-by":"publisher","first-page":"140","DOI":"10.34196\/IJM.00146","volume":"9","author":"A Ritter","year":"2016","unstructured":"Ritter A, Shukla N, Shanahan M, Van Hoang P, Lam Cao V, Perez P, M. Farrell. Building a microsimulation model of heroin use careers in Australia. Int J Microsimulation. 2016;9(3):140\u201376. https:\/\/doi.org\/10.34196\/IJM.00146.","journal-title":"Int J Microsimulation"},{"key":"1069_CR23","doi-asserted-by":"publisher","unstructured":"Shukla N, Van Hoang M, Shanahan M, Ritter A, Lam Cao V, Perez P. (2014). A lifetime individual sampling model (ISM) for heroin use and treatment evaluation in Australia. [https:\/\/doi.org\/10.13140\/2.1.1833.4404]","DOI":"10.13140\/2.1.1833.4404"},{"key":"1069_CR24","unstructured":"Public Health Agency of Canada. I-Track - Enhanced Surveillance of HIV, Hepatitis C and associated risk behaviours among people who inject drugs in Canada: Phase 2 Report 2014. https:\/\/www.canada.ca\/en\/public-health\/services\/hiv-aids\/publications\/i-track-enhanced-surveillance-hiv-hepatitis-associated-risk-behaviours-people-who-inject-drugs-canada-phase-2.html"},{"key":"1069_CR25","doi-asserted-by":"publisher","first-page":"102993","DOI":"10.1016\/j.drugpo.2020.102993","volume":"87","author":"AI Scheim","year":"2021","unstructured":"Scheim AI, Bouck Z, Tookey P, Hopkins S, Sniderman R, McLean E, et al. Supervised consumption service use and recent non-fatal overdose among people who inject drugs in Toronto, Canada. Int J Drug Policy. 2021;87:102993.","journal-title":"Int J Drug Policy"},{"issue":"4","key":"1069_CR26","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1007\/s11524-021-00547-w","volume":"98","author":"AI Scheim","year":"2021","unstructured":"Scheim AI, Sniderman R, Wang R, Bouck Z, McLean E, Mason K, et al. The Ontario Integrated Supervised Injection Services Cohort Study of People Who Inject Drugs in Toronto, Canada (OiSIS-Toronto): Cohort Profile. J Urban Health. 2021;98(4):538\u201350.","journal-title":"J Urban Health"},{"key":"1069_CR27","unstructured":"City of Toronto. Toronto Overdose Information System 2023. [https:\/\/www.toronto.ca\/community-people\/health-wellness-care\/health-inspections-monitoring\/toronto-overdose-information-system\/]."},{"key":"1069_CR28","doi-asserted-by":"crossref","unstructured":"Gomes T, Kitchen SA, Murray R. Measuring the Burden of opioid-related mortality in Ontario, Canada, during the COVID-19 pandemic. JAMA Netw Open. 2021;4(5).","DOI":"10.1001\/jamanetworkopen.2021.12865"},{"key":"1069_CR29","unstructured":"City of Toronto. Toronto Overdose Action Plan: Status Report 2020."},{"key":"1069_CR30","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1097\/00002030-200104003-00006","volume":"15","author":"CP Archibald","year":"2001","unstructured":"Archibald CP, Jayaraman GC, Major C, Patrick DM, Houston SM, Sutherland D. Estimating the size of hard-to-reach populations: a novel method using HIV testing data compared to other methods. Aids. 2001;15:S41\u20138.","journal-title":"Aids"},{"key":"1069_CR31","unstructured":"Remis RS, Strathdee SA, Millson M, Leclerc L, Degani N, Palmer RW et al. Consortium to characterize injection drug users in Montreal, Toronto and Vancouver, Canada. Contract for Health Canada. 1998."},{"key":"1069_CR32","volume-title":"Report of the Toronto and Ottawa supervised Consumption Assessment Study, 2012","author":"AM Bayoumi","year":"2012","unstructured":"Bayoumi AM, Bayoumi AM, Strike. C (co-principal investigators). In: Jairam J, Watson T, Enns E, Kolla G, Lee A, Shepherd S, Hopkins S, Millson M, Leonard L, Zaric G, Luce J, Degani N, Fischer B, Glazier R, O\u2019Campo P, Smith C, Penn R, Brandeau M, editors. Report of the Toronto and Ottawa supervised Consumption Assessment Study, 2012. Toronto, Ontario: St. Michael\u2019s Hospital and the Dalla Lana School of Public Health, University of Toronto; 2012."},{"key":"1069_CR33","unstructured":"McDonald K, Maghsoudi N, Thompson H, Werb D. What\u2019s in Toronto\u2019s drug supply? Results from samples checked by Toronto\u2019s drug checking service: October 10, 2019-March 31, 2020. Centre on Drug Policy Evaluation. Toronto. 2020."},{"issue":"11","key":"1069_CR34","doi-asserted-by":"publisher","first-page":"e1002973","DOI":"10.1371\/journal.pmed.1002973","volume":"16","author":"C Marks","year":"2019","unstructured":"Marks C, Borquez A, Jain S, Sun X, Strathdee SA, Garfein RS, et al. Opioid agonist treatment scale-up and the initiation of injection drug use: a dynamic modeling analysis. PLoS Med. 2019;16(11):e1002973.","journal-title":"PLoS Med"},{"key":"1069_CR35","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/j.drugalcdep.2018.12.018","volume":"197","author":"ML Mittal","year":"2019","unstructured":"Mittal ML, Jain S, Sun S, DeBeck K, Milloy MJ, Hayashi K, et al. Opioid agonist treatment and the process of injection drug use initiation. Drug Alcohol Depend. 2019;197:354\u20136.","journal-title":"Drug Alcohol Depend"},{"key":"1069_CR36","unstructured":"MATLAB version. 9.13. 0 (R2022b), Natick, Massachusetts: The MathWorks Inc.; 2022."},{"issue":"1","key":"1069_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-158-1-201301010-00003","volume":"158","author":"PO Coffin","year":"2013","unstructured":"Coffin PO, Sullivan SD. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann Intern Med. 2013;158(1):1\u20139.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1069_CR38","doi-asserted-by":"publisher","first-page":"295","DOI":"10.2466\/pr0.1998.83.1.295","volume":"83","author":"JB Murray","year":"1998","unstructured":"Murray JB. Effectiveness of methadone maintenance for heroin addiction. Psychol Rep. 1998;83(1):295\u2013302.","journal-title":"Psychol Rep"},{"key":"1069_CR39","doi-asserted-by":"publisher","first-page":"103680","DOI":"10.1016\/j.drugpo.2022.103680","volume":"104","author":"Z Bouck","year":"2022","unstructured":"Bouck Z, Scheim AI, Gomes T, Ling V, Caudarella A, Werb D. Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions. Int J Drug Policy. 2022;104:103680.","journal-title":"Int J Drug Policy"},{"issue":"10208","key":"1069_CR40","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1016\/S0140-6736(19)32232-9","volume":"394","author":"L Degenhardt","year":"2019","unstructured":"Degenhardt L, Wolfe D, Hall W, Hickman M, Chang J, Bruneau J, et al. Strategies to reduce drug-related harm: responding to the evidence base. Lancet. 2019;394(10208):1490\u20133.","journal-title":"Lancet"},{"key":"1069_CR41","unstructured":"Charlois T, editor. Safer nightlife in Europe. 5th Meeting EXASS Network; 2009."},{"key":"1069_CR42","doi-asserted-by":"publisher","first-page":"108374","DOI":"10.1016\/j.jsat.2021.108374","volume":"129","author":"C Russell","year":"2021","unstructured":"Russell C, Ali F, Nafeh F, Rehm J, LeBlanc S, Elton-Marshall T. Identifying the impacts of the COVID-19 pandemic on service access for people who use drugs (PWUD): a national qualitative study. J Subst Abuse Treat. 2021;129:108374.","journal-title":"J Subst Abuse Treat"},{"key":"1069_CR43","unstructured":"The Global Fund. Results Report 2021."}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01069-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-024-01069-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-024-01069-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T23:47:47Z","timestamp":1723506467000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-024-01069-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1069"],"URL":"https:\/\/doi.org\/10.1186\/s12954-024-01069-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4523641\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-4523641\/v1","asserted-by":"object"}]},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,13]]},"assertion":[{"value":"3 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"146"}}